Compounders Research Compare

Greenwich LifeSciences, Inc.(GLSI)

Biotechnology · Stafford, TX

$16.27-0.64 (-3.78%)

Delayed quote: Oct 6, 2026, 2:48 PM EDT

About Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.

Stafford, TX

13 employees

greenwichlifesciences.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Snehal S. Patel

View full financials

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T18:51:36.223Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:51:36.223Z.

Quote observation: 2026-10-06T18:48:15.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 238,814,444
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 8,876,353
TTM free cash flow · period ending 2026-06-30: -12,488,143

FMP input reference: b6268879a98e6c39cef7c3f9e2e80a63ea5355fd191f52e510f01db01fc6dd59

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

GLSI EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

GLSI Competitors' EV/FCF Ratio

Greenwich LifeSciences, Inc.

Current

Market Cap

$238.81M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

High Tide Inc.

Market Cap

$237.69M

EV/FCF Ratio

25.46x

TTM Avg

23.33x

3Y Avg

20.20x

5Y Avg

22.09x

Invivyd, Inc.

Market Cap

$237.22M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Galectin Therapeutics Inc.

Market Cap

$242.02M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CAMP4 Therapeutics Corporation

Market Cap

$236.58M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Akebia Therapeutics, Inc.

Market Cap

$236.39M

EV/FCF Ratio

3.36x

TTM Avg

5.14x

3Y Avg

5.14x

5Y Avg

5.14x

Lifecore Biomedical, Inc.

Market Cap

$242.50M

EV/FCF Ratio

N/A

TTM Avg

894.08x

3Y Avg

541.45x

5Y Avg

277.55x

Q32 Bio Inc.

Market Cap

$242.87M

EV/FCF Ratio

N/A

TTM Avg

9.08x

3Y Avg

9.08x

5Y Avg

9.08x

Utah Medical Products, Inc.

Market Cap

$235.40M

EV/FCF Ratio

20.58x

TTM Avg

10.38x

3Y Avg

8.72x

5Y Avg

10.56x

Nautilus Biotechnolgy, Inc.

Market Cap

$235.36M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Greenwich LifeSciences, Inc. (GLSI)	$238.81M	N/A	N/A	N/A	N/A
High Tide Inc. (HITI)vs ›	$237.69M	25.46x	23.33x	20.20x	22.09x
Invivyd, Inc. (IVVD)vs ›	$237.22M	N/A	N/A	N/A	N/A
Galectin Therapeutics Inc. (GALT)vs ›	$242.02M	N/A	N/A	N/A	N/A
CAMP4 Therapeutics Corporation (CAMP)vs ›	$236.58M	N/A	N/A	N/A	N/A
Akebia Therapeutics, Inc. (AKBA)vs ›	$236.39M	3.36x	5.14x	5.14x	5.14x
Lifecore Biomedical, Inc. (LFCR)vs ›	$242.50M	N/A	894.08x	541.45x	277.55x
Q32 Bio Inc. (QTTB)vs ›	$242.87M	N/A	9.08x	9.08x	9.08x
Utah Medical Products, Inc. (UTMD)vs ›	$235.40M	20.58x	10.38x	8.72x	10.56x
Nautilus Biotechnolgy, Inc. (NAUT)vs ›	$235.36M	N/A	N/A	N/A	N/A

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

Free Cash Flow FCF Yield P/FCF Ratio EV/EBITDA All Metrics